Lenalidomide down regulates IRF4 and SPIB, thereby increasing toxic IFNβ secretion and decreasing NF-κB activity which promotes apoptosis of ABC-DLBCL cells (90). This evidence concerns the gene NFKB1 and diffuse large B-cell lymphoma.